Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$1.5 million.

  • Inhibrx Biosciences' Change in Accured Expenses fell 125.12% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 94.18%. This contributed to the annual value of $35.9 million for FY2024, which is 37.64% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Change in Accured Expenses is -$1.5 million, which was up 64.73% from -$4.3 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Change in Accured Expenses high stood at $21.8 million for Q2 2024, and its period low was -$4.3 million during Q2 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $6.2 million (2023), whereas its average is $7.1 million.
  • Data for Inhibrx Biosciences' Change in Accured Expenses shows a maximum YoY plummeted of 125.12% (in 2025) over the last 5 years.
  • Inhibrx Biosciences' Change in Accured Expenses (Quarterly) stood at $17.4 million in 2023, then decreased by 5.05% to $6.0 million in 2024, then crashed by 125.12% to -$1.5 million in 2025.
  • Its Change in Accured Expenses stands at -$1.5 million for Q3 2025, versus -$4.3 million for Q2 2025 and $2.9 million for Q1 2025.